UPDATE 3-U.S. FDA panel: Novo Nordisk's liraglutide safe, effective for obesity

September 12, 2014 12:42 PM

14 0

* Analysts now see 90 to 95 percent chance of approval (Adds share price, Novo quote, background, analysts, bullet points)

WASHINGTON/COPENHAGEN, Sept 12 (Reuters) - Novo Nordisk's drug liraglutide is safe and effective enough to warrant approval for use in chronically obese patients with at least one weight-related health issue, an advisory panel to the U.S. Food and Drug Administration (FDA) said on Thursday.

Read more

To category page